Absci Corporation (ABSI) AI Stock Analysis

Absci Corporation is a Vancouver, Washington-based drug and target discovery company founded in 2011. The company specializes in delivering biologic drug candidates and production cell lines via its integrated drug creation platform. By combining drug discovery and cell line development into a unified workflow, Absci seeks to accelerate timelines and optimize efficiency from discovery to production. The platform provides biopharmaceutical partners in the United States with capabilities designed to handle complex research and production demands, with an overarching focus on advancing biotechnology and improving patient outcomes worldwide.

Absci's annual revenue dropped from $4.8M in FY2021 to $2.8M in FY2025, translating to a 5-year revenue CAGR of -10.1%. Revenue contracted 20.7% in FY2024 to $4.5M and fell 38.2% in FY2025 to $2.8M. Operating margins were consistently negative, reaching -4454.2% in FY2025 as net income was -$115.2M and R&D expenses rose to $81.4M. For the trailing twelve months, revenue was $1.6M with EPS of -$0.79. In the latest quarter ended June 30, 2026, quarterly revenue fell 46.4% year-over-year.

As of June 30, 2026, Absci held $201.1M in cash and short-term investments against total debt of $3.7M, yielding net cash of $197.5M. The company shows strong balance sheet liquidity with a current ratio of 10.63 and a debt-to-equity ratio of 0.01 on shareholders' equity of $246.1M. Cash burn remains substantial, with operating cash flow of -$92.9M and free cash flow of -$94.0M in FY2025, alongside capital expenditures of $1.1M. Over five years, the company's share count expanded by 75.4%.

With a market cap of $1.42B and enterprise value of $1.48B, Absci trades at a price-to-sales multiple of 907.0x and an EV-to-revenue multiple of 944.9x, significantly above the median of its US-listed Healthcare peers at 4.1x sales. Its price-to-book ratio is 6.8x. Over the past year, the stock gained 69.4%, outperforming the S&P 500 return of 16.8%. However, its 5-year return of -22.4% lagged the benchmark's 83.0% gain. The stock has a beta of 2.28.

Wall Street analysts hold a positive outlook on Absci, with 8 Strong Buy, 2 Buy, and 1 Hold ratings. The mean price target of $14.90 implies an 80.6% upside from the last close of $8.25. For the current fiscal year ending December 31, 2026, consensus estimates project revenue of $3.9M and an EPS of -$0.81. For the following fiscal year, 7 analysts project revenue to expand 310.9% to $16.0M. The company beat EPS estimates in 2 of the last 4 quarters, with the next earnings date scheduled for November 12, 2026.

This page is an AI-written research summary of Absci Corporation (ABSI). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ABSI income statement, ABSI balance sheet, ABSI key metrics, ABSI analyst forecast, ABSI chart. See the ABSI stock overview for the latest quote and news.